Mini-Focus Issue: Acute Myocardial InfarctionClinical ResearchFour-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated With BallOON Angioplasty)
Clinical Research
Under an Elsevier user license
open archive
Key Words
bare-metal stent
percutaneous coronary intervention
sirolimus-eluting coronary stent
target lesion revascularization
Abbreviations and Acronyms
ARC
Academic Research Consortium
BMS
bare-metal stent(s)
CI
confidence interval
DES
drug-eluting stent(s)
HR
hazard ratio
MI
myocardial infarction
PCI
percutaneous coronary intervention
SES
sirolimus-eluting stent(s)
STEMI
ST-segment elevation myocardial infarction
TLR
target lesion revascularization
Cited by (0)
The TYPHOON trial was an investigator-initiated trial sponsored by Cordis Corporation, a Johnson & Johnson company. Dr. Spaulding was a member of a Cordis scientific advisory board; has received honorarium from Cordis for speaker's fees; and has been a full-time employee of the Cordis Corporation since June 1, 2010. Dr. Varenne is a speaker for Cordis, Boston Scientific, and Abbott. Drs. Cebrian, Wang, and Stoll are full-time employees of the Cordis Corporation and have Johnson & Johnson stock options. Dr. Fajadet is a consultant for Cordis and Abbott. Dr. Erglis is on the advisory board for Cordis. Dr. Hosten is employed by the Cordis Corporation as a consultant. Dr. Henry is part of the Cordis Exchange program.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.